Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00552344 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

A Phase 3 study, sponsored by UCB Biosciences.

Completed
Registry status
Phase 3
Development phase
403
Enrollment target

NCT00552344: Completed Phase 3 study, sponsored by UCB Biosciences.

NCT00552344 is a Phase 3 study that has completed, run by UCB Biosciences. The registered enrollment target is 403 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00552344, a Phase 3 study, has completed, sponsored by UCB Biosciences.

COMPLETED
Registry status
Phase 3
Development phase
403 participants
Enrollment target

Study Summary

The primary objective of the study is to assess the safety of long term therapy with Certolizumab Pegol in those subjects participating in study C87085 \[NCT00552058\].

Primary Outcome

An AE is defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

Interventions

  • BIOLOGICAL Cimzia

Trial Details

FieldValue
Enrollment Target 403 participants
Start Date 2008-05
Est. Completion 2014-12
Phase Phase 3
UCB Biosciences

39 total trials

What the finished NCT00552344 record still lists

NCT00552344 is an interventional study that assigns participants to a tested intervention. The registered 403 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower).

The record links to 0 conditions, and to 1 intervention - of which Cimzia is the first listed.

NCT00552344 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00552344 about?

NCT00552344 is a clinical study titled "A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease". The primary objective of the study is to assess the safety of long term therapy with Certolizumab Pegol in those subjects participating in study C87085 \[NCT00552058\].

What is the current status of trial NCT00552344?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 403 participants. The study started on 2008-05. Estimated completion is 2014-12.

What interventions are being tested in trial NCT00552344?

The interventions under investigation include: Cimzia (BIOLOGICAL).

Who is sponsoring clinical trial NCT00552344?

This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00552344's enrollment target sits among peer trials

403 917th of 2000 higher than 1,082 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05647122 · 403 participants · Phase 1

    First in Human Study of AZD9592 in Solid Tumors

  • NCT05674799 · 403 participants · NA

    NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks

  • NCT06244771 · 403 participants · Phase 1

    A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

  • NCT05049057 · 404 participants · Phase 2

    Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00552344, the US trial registry maintained by the National Library of Medicine. NCT00552344 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.